{
    "id": "13e38542-4057-4ca5-bec5-6fa01e3f6cd0",
    "indications": {
        "text": "jatenzo ( testosterone undecanoate ) androgen indicated testosterone replacement therapy adult males conditions associated deficiency absence endogenous testosterone : primary hypogonadism ( congenital acquired ) : testicular failure due conditions cryptorchidism , bilateral torsion , orchitis , vanishing testis syndrome , orchiectomy , klinefelter syndrome , chemotherapy , toxic damage alcohol heavy metals . men usually low serum testosterone concentrations gonadotropins ( follicle-stimulating hormone [ fsh ] , luteinizing hormone [ lh ] ) normal range . hypogonadotropic hypogonadism ( congenital acquired ) : gonadotropin luteinizing hormone-releasing hormone ( lhrh ) deficiency pituitary-hypothalamic injury causes tumors , trauma , radiation . men low testosterone serum concentrations gonadotropins normal low range . limitations : safety efficacy jatenzo men \u201c age-related hypogonadism \u201d established . safety efficacy jatenzo males less 18 years old established [ ( 8.4 ) ] .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            },
            {
                "text": "cryptorchidism (DOID:11383)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11383"
            },
            {
                "text": "orchitis (DOID:2518)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2518"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "klinefelter syndrome (DOID:1921)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1921"
            },
            {
                "text": "hypogonadotropic hypogonadism (DOID:0090070)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0090070"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prior initiating jatenzo , confirm diagnosis hypogonadism ensuring serum testosterone concentrations measured morning least two separate days concentrations normal range ( 2.1 ) . take jatenzo food ( 2.2 ) . starting dose : 237 mg orally morning evening . adjust dose minimum 158 mg twice daily maximum 396 mg twice daily based serum testosterone drawn 6 hours morning dose least 7 days starting treatment following dose adjustment periodically thereafter ( 2.2 ) .",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "jatenzo ( testosterone undecanoate ) capsules available three strengths 158 mg , 198 mg , 237 mg. capsules packaged 120 units wide-mouth , round , white hdpe bottles white , polypropylene , child resistant caps induction-sealed liner . 158 mg capsules opaque red capsules imprinted \u201c 158 \u201d white ink supplied bottles : ndc 69087-158-12 . 198 mg capsules opaque white capsules imprinted \u201c 198 \u201d red ink supplied bottles : ndc 69087-198-12 . 237 mg capsules opaque orange capsules imprinted \u201c 237 \u201d white ink supplied bottles : ndc 69087-237-12. keep jatenzo reach children . store 20\u00b0c 25\u00bac ( 68\u00b0f 77\u00baf ) , excursions permitted 15\u00bac 30\u00bac ( 59\u00baf 86\u00baf ) . avoid exposing capsules moisture ( store dry place ) .",
    "adverseReactions": "jatenzo contraindicated : men carcinoma breast known suspected carcinoma prostate [ ( 5.3 ) ] . women pregnant . testosterone cause virilization female fetus administered pregnant woman [ ( 8.1 ) ] . men known hypersensitivity jatenzo ingredients [ description ( 11 ) ] .",
    "ingredients": [
        {
            "name": "TESTOSTERONE UNDECANOATE",
            "code": "H16A5VCT9C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135741"
        },
        {
            "name": "OLEIC ACID",
            "code": "2UMI9U37CP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16196"
        },
        {
            "name": "POLYOXYL 40 HYDROGENATED CASTOR OIL",
            "code": "7YC686GQ8F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_140618"
        },
        {
            "name": "BORAGE OIL",
            "code": "F8XAG1755S",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11238"
        },
        {
            "name": "PEPPERMINT OIL",
            "code": "AV092KU4JH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11198"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_24751"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "organization": "TOLMAR Inc.",
    "name": "Jatenzo",
    "effectiveTime": "20250516",
    "indications_original": "JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:\n\n                  \n                     Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.  These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.\n    \n                     Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from causes such as tumors, trauma, or radiation.  These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.\n    \n                  \n                  \n                     Limitations of use:\n                  \n                  \n                     Safety and efficacy of JATENZO in men with \u201cage-related hypogonadism\u201d have not been established.\n                     Safety and efficacy of JATENZO in males less than 18 years old have not been established [see \n                        Use in Specific Populations (8.4)].",
    "contraindications_original": "Prior to initiating JATENZO, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these concentrations are below the normal range ( 2.1 ). Take JATENZO with food ( 2.2 ). Starting dose: 237 mg orally once in the morning and once in the evening. Adjust the dose to a minimum of 158 mg twice daily and a maximum of 396 mg twice daily based on serum testosterone drawn 6 hours after the morning dose at least 7 days after starting treatment or following dose adjustment and periodically thereafter ( 2.2 ).",
    "warningsAndPrecautions_original": "JATENZO (testosterone undecanoate) capsules are available in three strengths of 158 mg, 198 mg, and 237 mg.  Capsules are packaged as 120 units in wide-mouth, round, white HDPE bottles with white, polypropylene, child resistant caps and induction-sealed liner.\n\n                  158 mg capsules are opaque red capsules imprinted with \u201c158\u201d in white ink and are supplied in bottles: NDC 69087-158-12.\n\n                  198 mg capsules are opaque white capsules imprinted with \u201c198\u201d in red ink and are supplied in bottles: NDC 69087-198-12.\n\n                  237 mg capsules are opaque orange capsules imprinted with \u201c237\u201d in white ink and are supplied in bottles: NDC 69087-237-12.\n\n                  \n                     Keep JATENZO out of reach of children.\n                  \n                  Store at 20\u00b0C to 25\u00baC (68\u00b0F to 77\u00baF), excursions permitted to 15\u00baC to 30\u00baC (59\u00baF to 86\u00baF).  Avoid exposing the capsules to moisture (store in a dry place).",
    "adverseReactions_original": "JATENZO is contraindicated in:\n\n                  \n                     Men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions (5.3)].\n    \n                     Women who are pregnant.  Testosterone can cause virilization of the female fetus when administered to a pregnant woman [see Use in Specific Populations (8.1)].\n    \n                     Men with known hypersensitivity to JATENZO or any of its ingredients [see Description (11)].",
    "drug": [
        {
            "name": "Jatenzo",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135741"
        }
    ]
}